What is Drixoral used for?

Drixoral is indicated for Allergic conjunctivitis, Allergic rhinitis, Dermatographic urticaria, Influenza-like symptoms, Itching of skin.

Drixoral is developed by Merck & Co..

What development phase is Drixoral in?

Drixoral is FDA-approved (marketed).

What is the generic name of Drixoral?

DEXBROMPHENIRAMINE is the generic (nonproprietary) name of Drixoral.

Last reviewed 2026-04-20 · How we verify

Drixoral (DEXBROMPHENIRAMINE)

Merck & Co. · FDA-approved approved Small molecule Quality 27/100

At a glance

Generic name	DEXBROMPHENIRAMINE
Sponsor	Merck & Co.
Drug class	dexbrompheniramine
Target	Histamine H1 receptor
Modality	Small molecule
Therapeutic area	Infectious Disease
Phase	FDA-approved
First approval	1963

Approved indications

Allergic conjunctivitis
Allergic rhinitis
Dermatographic urticaria
Influenza-like symptoms
Itching of skin
Seasonal allergic rhinitis
Urticaria
Vasomotor rhinitis

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Drixoral CI brief — competitive landscape report
Drixoral updates RSS · CI watch RSS
Merck & Co. portfolio CI